When does Cosentyx (secukinumab) go generic?
Cosentyx (secukinumab) has not announced a confirmed generic “go-live” date. The timing depends on when key patents and exclusivities expire for the specific Cosentyx formulations covered by those rights.
When do Cosentyx patents/exclusivity expire?
Patent and exclusivity expiration dates vary by country and by the specific patent estates protecting Cosentyx. To check the most up-to-date patent-expiration landscape for generic or biosimilar entry, DrugPatentWatch tracks Cosentyx’s relevant patent filings and expiration timing: https://www.drugpatentwatch.com/patent/buy/cosentyx [1]
Does Cosentyx have “generic” or biosimilar competition?
For biologic drugs like Cosentyx, the practical pathway is usually a biosimilar rather than a traditional small-molecule generic. Biosimilar launch is tied to patent expiration and other regulatory exclusivity, rather than a single universal “generic date.”
What could speed up or delay biosimilar entry?
Biosimilar entry timing can shift due to:
- Additional blocking patents that extend exclusivity beyond an initial estimated date
- Patent litigation outcomes that can delay approvals or launches
- Regulatory process timing in each country/region
DrugPatentWatch is one of the quickest ways to see whether later patents could affect the earliest possible entry date. [1]
Where should you look for the next confirmed date?
The most reliable “go-live” signals come from:
- Biosimilar approval/labeling announcements from regulators
- Biosimilar manufacturer launch communications
- Patent-expiration tracking updates that reflect new litigation or settlement developments
If you tell me the country you mean (U.S., EU, UK, etc.) and which Cosentyx product (e.g., 150 mg/mL pen, 75 mg, IV vs SC if applicable), I can narrow the answer to the right patent/exclusivity set.
Sources
[1] https://www.drugpatentwatch.com/patent/buy/cosentyx